Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 10/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 9/20 | 0.38 |
| ▸ | RARG | P13631 | 9/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12364987 | 0.89 | RARB (0.48) | MAPTALDH1A1NPC1RAB9ASRD5A2 | |
| SCHEMBL12365082 | 0.87 | ESR2 (0.46) | ALDH1A1SRD5A2SRD5A1RARBESR2 | |
| SCHEMBL12365039 | 0.87 | TDP2 (0.42) | MAPTNPC1RAB9ASRD5A2SRD5A1 | |
| SCHEMBL12364994 | 0.86 | SRD5A2 (0.49) | ALDH1A1SRD5A2SRD5A1RARBRARA | |
| SCHEMBL12388903 | 0.85 | RARA (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2RARB | |
| SCHEMBL12365032 | 0.85 | SLC6A3 (0.45) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12365695 | 0.85 | RARB (0.50) | MAPTALDH1A1NPC1RAB9ASRD5A2 | |
| SCHEMBL12365524 | 0.84 | PTGS2 (0.43) | ALDH1A1SRD5A2SRD5A1RARBRARA | |
| SCHEMBL12365064 | 0.84 | RARB (0.39) | ALDH1A1NPC1RAB9ASRD5A2SRD5A1 | |
| SCHEMBL12365158 | 0.83 | CYP3A4 (0.49) | MAPTALDH1A1SRD5A2SRD5A1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPT 463/4885ALDH1A1 934/4885NPC1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.